Powered by: Motilal Oswal
2026-04-13 11:13:17 am | Source: Accord Fintech
Heranba Industries jumps on entering into fast-growing crop nutrition segment
Heranba Industries jumps on entering into fast-growing crop nutrition segment

Heranba Industries is currently trading at Rs. 203.00, up by 10.35 points or 5.37% from its previous closing of Rs. 192.65 on the BSE.

The scrip opened at Rs. 188.00 and has touched a high and low of Rs. 206.85 and Rs. 188.00 respectively. So far 3032 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 403.40 on 31-Jul-2025 and a 52 week low of Rs. 155.80 on 30-Mar-2026.

Last one week high and low of the scrip stood at Rs. 206.85 and Rs. 174.00 respectively. The current market cap of the company is Rs. 794.47 crore.

The promoters holding in the company stood at 74.94%, while Institutions and Non-Institutions held 0.15% and 24.91% respectively.

Heranba Industries has entered into the fast-growing crop nutrition segment, marking a significant milestone in its growth journey. The company has unveiled a premium portfolio of innovative crop nutrition solutions aimed at enhancing farm productivity across India and global markets.

The company introduced two breakthrough products namely Fentaamine--A next-generation bio stimulant engineered to enhance plant metabolism, improve stress tolerance, and boost crop yield; and MycoHil--An advanced biofertilizer designed to improve nutrient absorption, strengthen soil microbiology, and promote sustainable agriculture practices. These products have been developed in collaboration with a leading American multinational company, combining global research expertise with Heranba’s robust manufacturing capabilities.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here